Compare · NAGE vs RGC
NAGE vs RGC
Side-by-side comparison of Niagen Bioscience Inc. (NAGE) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAGE and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $2.74B, about 10.6x NAGE ($258.7M).
- Over the past year, NAGE is down 67.5% and RGC is down 59.0% - RGC leads by 8.5 points.
- NAGE has hit the wire 7 times in the past 4 weeks while RGC has been quiet.
- NAGE has more recent analyst coverage (1 ratings vs 0 for RGC).
PerformanceNAGE-67.53%RGC-59.04%
2025-08-26+0.00%2026-08-25
- Company
- Niagen Bioscience Inc.
- Regencell Bioscience Holdings Limited
- Price
- -
- -
- Market cap
- $258.7M
- $2.74B
- 1M return
- +1.08%
- -5.31%
- 1Y return
- -67.53%
- -59.04%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 1
- 0
Latest NAGE
- Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
- Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
- Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
- Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
- Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
- Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
- Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited